Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Docetaxel
Drug ID BADD_D00699
Description Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Indications and Usage For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Marketing Status approved; investigational
ATC Code L01CD02
DrugBank ID DB01248
KEGG ID D02165; D07866
MeSH ID D000077143
PubChem ID 148124
TTD Drug ID D0O5WP
NDC Product Code 0955-1020; 43066-001; 43598-259; 0409-0367; 70121-1222; 70700-175; 68554-0075; 43598-389; 45963-765; 72485-216; 17359-9100; 43598-610; 43598-611; 47335-895; 55150-378; 57884-3041; 57884-3042; 68083-399; 68083-400; 57884-3043; 70121-1221; 72485-214; 54893-0008; 65129-1298; 16729-267; 55150-380; 62332-678; 0143-9205; 43066-006; 68083-401; 0409-4235; 70121-1223; 43066-010; 55150-379; 66758-950; 0409-0368; 70700-174; 46708-678; 47335-323; 67457-781; 0409-0366; 65129-1141; 45963-734; 0409-0365; 70700-176; 0955-1021; 65129-1189; 66758-050; 0409-5068; 72485-215; 0955-1022; 0143-9204; 43598-258; 47335-939
UNII 15H5577CQD
Synonyms Docetaxel | Docetaxel Trihydrate | Docetaxol | Docetaxel Hydrate | Taxoltere Metro | RP 56976 | RP-56976 | RP56976 | Taxotere | Docetaxel Anhydrous | N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol | N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol | NSC 628503
Chemical Information
Molecular Formula C43H53NO14
CAS Registry Number 114977-28-5
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O) O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral swelling02.05.04.015; 08.01.03.053--Not Available
Weight fluctuation14.03.02.002--Not Available
Neutropenic sepsis11.01.11.006; 01.02.03.007--Not Available
Onychomadesis23.02.05.006--
Left ventricular dysfunction02.04.02.011--
Deep vein thrombosis24.01.02.003--Not Available
Fluid imbalance14.05.01.003--Not Available
Central nervous system lesion17.02.10.011--Not Available
Malignant neoplasm progression16.16.01.005--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Necrotising colitis07.08.01.013--Not Available
Upper respiratory tract congestion22.12.03.033--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Dacryostenosis acquired06.06.04.003--Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Necrotising enterocolitis neonatal18.04.11.002; 07.08.03.011--Not Available
Haemorrhage24.07.01.002--Not Available
Cutaneous lupus erythematosus10.04.03.007; 23.03.02.008; 15.06.02.007--Not Available
Colitis microscopic07.08.01.011--Not Available
Cancer pain16.32.03.004--Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.010--Not Available
Lung neoplasm malignant16.19.02.001; 22.08.01.001--Not Available
Nail toxicity23.02.05.016; 12.03.01.045--Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.004--Not Available
Epidermal necrosis23.03.03.035--Not Available
Neutropenic infection11.01.08.024; 01.02.03.009--Not Available
Skin toxicity23.03.03.032; 12.03.01.020--Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene